• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Genetic Leap, Eli Lilly Partner to Advance RNA Genetic Medicine

by Jasmine Pennic 09/05/2024 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know: 

– Genetic Leap, a pioneering AI-native techbio company, has entered into a strategic research collaboration with Eli Lilly and Company. 

– The partnership aims to develop innovative genetic medicine therapeutics using Genetic Leap’s cutting-edge RNA-targeted AI platform.

Leveraging AI to Revolutionize RNA Drug Discovery

RNA genetic medicine holds immense promise for addressing a wide range of diseases. By targeting RNA, scientists can potentially develop therapies for conditions such as cancer, genetic disorders, and infectious diseases.

RNA plays a crucial role in regulating gene expression and protein production. By targeting RNA, scientists can potentially develop new therapies for diseases that have been difficult to treat with traditional drugs. However, drugging RNA has presented significant challenges due to its complex structure and interactions.

Genetic Leap’s AI platform is revolutionizing the approach to RNA drug discovery. By utilizing advanced AI algorithms, the platform can identify novel RNA targets and design potential drug candidates with high specificity and efficacy.

 Eli Lilly Collaboration

The collaboration between Genetic Leap and Eli Lilly builds upon a successful pilot project and will focus on developing genetic medicine therapeutics for high-priority therapeutic areas. Genetic Leap will receive up to $495M in funding from Eli Lilly, including upfront payments and milestone payments, as well as tiered royalties.

“We are thrilled to collaborate with Lilly and deeply share their strong commitment to developing RNA medicines,” said Dr. Bertrand Adanve, CEO and founder of Genetic Leap. “Our primary goal in building the Genetic Leap AI platform is to accelerate the development of life-saving medicines for patients, and this collaboration with Lilly’s talented and savvy R&D team takes us significantly closer to that goal.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Interview

Reach7 Diabetes Studios Founder Chun Yong on Reimagining Chronic Care with a Concierge Medical Model

Most-Read

Bayer Exits Radiology AI Market, Discontinuing Calantic and Blackford

Bayer Exits Radiology AI Market, Discontinuing Calantic and Blackford

Oracle Health Launches AI Center of Excellence for Healthcare

Oracle Health Launches AI Center of Excellence for Healthcare

Particle Health Addresses Integration to Epic Data Despite Dispute

US Court Allows Particle’s Antitrust Claims Against Epic to Proceed

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Preparing for the ‘Big Beautiful Bill’: How Digitization Can Streamline Medicaid Eligibility & Social Care Delivery

Preparing for the ‘Big Beautiful Bill’: How Digitization Can Streamline Medicaid Eligibility & Social Care Delivery

Evernorth Health Services Invests $3.5B in Shields Health Solutions

Evernorth Health Services Invests $3.5B in Shields Health Solutions

KLAS Report: Oracle Health Faces Customer Losses and Declining Satisfaction

KLAS Report: Oracle Health Faces Customer Losses and Declining Satisfaction

Tempus AI Acquires Digital Pathology Leader Paige for $81.25M

M&A:Tempus AI Acquires Digital Pathology Leader Paige for $81.25M

Mira Launches Ultra4™, the First At-Home Hormone Monitor with Lab-Quality Insights

Femtech: Mira Launches Ultra4™, the First At-Home Hormone Monitor with Lab-Quality Insights

How Healthcare CIOs Can Solve the Unstructured Data Crisis and Reduce Storage Costs

How Healthcare CIOs Can Solve the Unstructured Data Crisis and Reduce Storage Costs

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |